In order to overcome the cardiotoxicity induced by IC blockers different strategies can be applied (D’Amico et al., 2013): i) using non torsadogenic blockers; ii) using state-specific blockers such as R-roscovitine (Ganapathi et al., 2009); iii) using tumour-specific drugs such as CD 160130 (Gasparoli et al., 2015); iv) using monoclonal antibodies (Iorio et al., 2019) and v) using bispecific antibodies directed against tumour-specific macromolecular complexes such as the Kv11.1/β1 integrin complex (Duranti et al., 2021a; 2021b; Iorio et al., 2022; Lottini et al., 2023). Here, KCNH2 is linked to neoplasm.